Role of immunomarkers in the clinicopathological analysis of unicystic ameloblastoma

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose. The clinical behavior of unicystic ameloblastomavaries according to its subtype. Theassessment of its proliferative capacity, neovascularization, and invasiveness using relevant immunomarkers may aid in appropriate surgical therapeutic protocol. Methods. 18 cases of clinically and histologically confirmed unicystic ameloblastoma, categorized as luminal, intraluminal, ormural subtypes, were analyzed retrospectively. Immunomarkers such as Ki-67, CD34, MMP-2, and MMP-9 were studied to evaluate their behavior. Results. Labeling index of Ki-67 was 4.25% in the intraluminal subtype, compared with 2.14%in the luminal and 4.04% in themural variant (P = 0.3). CD34 immunostaining was significantly higher in the mural variant (43 per high power field) than the other two subtypes (P = 0.04). MMP-2 and MMP-9 were strongly expressed in mural, moderately in intraluminal, and weakly to absent in luminal variant. Conclusions. High proliferative index, angiogenesis, and protease activity in themural ameloblastoma, ascertained by the expression of these markers, confirm its aggressive phenotype. The intraluminal and luminal subtype exhibiting decreased expression are compatible with their indolent clinical behavior.

Original languageEnglish
Pages (from-to)481-488
Number of pages8
JournalDisease Markers
Volume35
Issue number5
DOIs
Publication statusPublished - 2013

Fingerprint

Ameloblastoma
Matrix Metalloproteinases
Labeling
Peptide Hydrolases
Phenotype

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

@article{79303872e2cf40edbda1e985ebfd7000,
title = "Role of immunomarkers in the clinicopathological analysis of unicystic ameloblastoma",
abstract = "Purpose. The clinical behavior of unicystic ameloblastomavaries according to its subtype. Theassessment of its proliferative capacity, neovascularization, and invasiveness using relevant immunomarkers may aid in appropriate surgical therapeutic protocol. Methods. 18 cases of clinically and histologically confirmed unicystic ameloblastoma, categorized as luminal, intraluminal, ormural subtypes, were analyzed retrospectively. Immunomarkers such as Ki-67, CD34, MMP-2, and MMP-9 were studied to evaluate their behavior. Results. Labeling index of Ki-67 was 4.25{\%} in the intraluminal subtype, compared with 2.14{\%}in the luminal and 4.04{\%} in themural variant (P = 0.3). CD34 immunostaining was significantly higher in the mural variant (43 per high power field) than the other two subtypes (P = 0.04). MMP-2 and MMP-9 were strongly expressed in mural, moderately in intraluminal, and weakly to absent in luminal variant. Conclusions. High proliferative index, angiogenesis, and protease activity in themural ameloblastoma, ascertained by the expression of these markers, confirm its aggressive phenotype. The intraluminal and luminal subtype exhibiting decreased expression are compatible with their indolent clinical behavior.",
author = "Parul Sah and Aparna Menon and Asha Kamath and Chetana Chandrashekar and Sunitha Carnelio and Raghu Radhakrishnan",
year = "2013",
doi = "10.1155/2013/517834",
language = "English",
volume = "35",
pages = "481--488",
journal = "Disease Markers",
issn = "0278-0240",
publisher = "IOS Press",
number = "5",

}

Role of immunomarkers in the clinicopathological analysis of unicystic ameloblastoma. / Sah, Parul; Menon, Aparna; Kamath, Asha; Chandrashekar, Chetana; Carnelio, Sunitha; Radhakrishnan, Raghu.

In: Disease Markers, Vol. 35, No. 5, 2013, p. 481-488.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Role of immunomarkers in the clinicopathological analysis of unicystic ameloblastoma

AU - Sah, Parul

AU - Menon, Aparna

AU - Kamath, Asha

AU - Chandrashekar, Chetana

AU - Carnelio, Sunitha

AU - Radhakrishnan, Raghu

PY - 2013

Y1 - 2013

N2 - Purpose. The clinical behavior of unicystic ameloblastomavaries according to its subtype. Theassessment of its proliferative capacity, neovascularization, and invasiveness using relevant immunomarkers may aid in appropriate surgical therapeutic protocol. Methods. 18 cases of clinically and histologically confirmed unicystic ameloblastoma, categorized as luminal, intraluminal, ormural subtypes, were analyzed retrospectively. Immunomarkers such as Ki-67, CD34, MMP-2, and MMP-9 were studied to evaluate their behavior. Results. Labeling index of Ki-67 was 4.25% in the intraluminal subtype, compared with 2.14%in the luminal and 4.04% in themural variant (P = 0.3). CD34 immunostaining was significantly higher in the mural variant (43 per high power field) than the other two subtypes (P = 0.04). MMP-2 and MMP-9 were strongly expressed in mural, moderately in intraluminal, and weakly to absent in luminal variant. Conclusions. High proliferative index, angiogenesis, and protease activity in themural ameloblastoma, ascertained by the expression of these markers, confirm its aggressive phenotype. The intraluminal and luminal subtype exhibiting decreased expression are compatible with their indolent clinical behavior.

AB - Purpose. The clinical behavior of unicystic ameloblastomavaries according to its subtype. Theassessment of its proliferative capacity, neovascularization, and invasiveness using relevant immunomarkers may aid in appropriate surgical therapeutic protocol. Methods. 18 cases of clinically and histologically confirmed unicystic ameloblastoma, categorized as luminal, intraluminal, ormural subtypes, were analyzed retrospectively. Immunomarkers such as Ki-67, CD34, MMP-2, and MMP-9 were studied to evaluate their behavior. Results. Labeling index of Ki-67 was 4.25% in the intraluminal subtype, compared with 2.14%in the luminal and 4.04% in themural variant (P = 0.3). CD34 immunostaining was significantly higher in the mural variant (43 per high power field) than the other two subtypes (P = 0.04). MMP-2 and MMP-9 were strongly expressed in mural, moderately in intraluminal, and weakly to absent in luminal variant. Conclusions. High proliferative index, angiogenesis, and protease activity in themural ameloblastoma, ascertained by the expression of these markers, confirm its aggressive phenotype. The intraluminal and luminal subtype exhibiting decreased expression are compatible with their indolent clinical behavior.

UR - http://www.scopus.com/inward/record.url?scp=84890386608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890386608&partnerID=8YFLogxK

U2 - 10.1155/2013/517834

DO - 10.1155/2013/517834

M3 - Article

C2 - 24223460

AN - SCOPUS:84890386608

VL - 35

SP - 481

EP - 488

JO - Disease Markers

JF - Disease Markers

SN - 0278-0240

IS - 5

ER -